Canagliflozin Patent Expiration
Canagliflozin is used for the treatment of type 2 diabetes mellitus and reduction of cardiovascular and kidney-related risks. It was first introduced by Janssen Pharmaceuticals Inc
Canagliflozin Patents
Given below is the list of patents protecting Canagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Invokana | US10617668 | Pharmaceutical formulations | May 11, 2031 | Janssen Pharms |
| Invokana | US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | Feb 26, 2029 | Janssen Pharms |
| Invokana | US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | Dec 03, 2027 | Janssen Pharms |
| Invokana | US7943788 | Glucopyranoside compound | Jul 14, 2027 | Janssen Pharms |
| Invokana | US8222219 | Glucopyranoside compound | Apr 11, 2025 | Janssen Pharms |
Canagliflozin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List